# EISMEA

> EISMEA is a VC fund backing Health Care, Biotechnology and Medical. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 7
- Last investment: Apr 2022
- Lead investor: 43%
- Last updated: Aug 2026

EISMEA is a VC fund focused on Health Care and Biotechnology.

## Contacts

5 contacts available for EISMEA. Shizune tracks 2 team members at EISMEA. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/EISMEA?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 43% |
| Biotechnology | 3 | 43% |
| Medical | 2 | 29% |
| Manufacturing | 2 | 29% |
| Medical Device | 2 | 29% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 5 | 71% |
| Seed | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Denmark | 2 | 29% |
| Italy | 1 | 14% |
| France | 1 | 14% |
| Israel | 1 | 14% |
| Finland | 1 | 14% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Cristian Dascalu | EIC Ambassador for Eastern Europe | 3 | https://shizune.co/investors/profile/cristian-dascalu |
| Monique Calisti | Expert evaluator and reviewer | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AGADE | AGADE specialising in robotic exoskeletons. The company created its first product, AGADEXO, which can significantly reduce muscle fatigue and the risk of injury associated with repetitive and dynamic activities. They provide variable support, eliminating the effect of gravity on human limbs and allowing movements comparable to those possible in azero-g environment. | $9M | Venture - Series Unknown | Apr 14, 2022 |  |
| BroadBit Batteries | BroadBit Batteries is developing revolutionary new batteries using novel sodium-based chemistries to power the future green economy. They are developing revolutionary new batteries using novel sodium-based chemistries to power the future green economy.They have already made high-performance lab samples and are now commercializing the technologyfor next-generation electric vehicles, portable electronics, starters, and grid energy storage. | $2.8M | Grant | Dec 20, 2021 |  |
| Aenitis Technologies | Created in July 2014, Aenitis Technologies is a French start-up resulting from the work of Mauricio HOYOS and Jean-Luc AIDER, both CNRS researchers at the PMMH Laboratory (Physics and Mechanics of Heterogeneous Media at the ESPCI ParisTech, a research engineer’s school in Paris. The company focuses on medical devices’ area, where their breakthroughtechnologies are highly promising. Aenitis Technologies is developing innovative separation, manipulation and filtration of biological elements solutions, based on acoustophoresis technologies. The company first focuses on technological solutions that will revolutionize current practices in Public Health. Aenitis Technologies aims to become a world leader in filtering / separating solutions by acoustophoresis. |  | Grant | Jun 16, 2021 |  |
| Orthox Ltd. | Founded to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way cartilage injuries are treated. Trauma and erosion of the smooth, stiff cartilage in our joints leads to Osteoarthritis (OA) a debilitating disease, which affects over 300 million patients globally and costs the US economy alone over $128billion each year. Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox’s exceptionally strong, resilient, regenerative hydrogel technology, FibroFix™ achieves both these goals, offering a unique solution for the millions of patients suffering from damage to their joints. Initially targeting the knee, Orthox has developed a compelling set of data on lead product FibroFix™ Cartilage which has secured major awards from multiple funding bodies and will shortly enter clinical trials. FibroFix™ technology will then be rolled out to treat other joints and Orthox also has pipeline developments beyond orthopaedics in which strength and tissue regeneration are key. Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFix™, will be the fastest growing market segment. Orthox: Reducing Pain, Increasing Mobility, Regenerating Strength™. | $2.8M | Grant | Jul 01, 2020 |  |
| Vital Beats | Vital Beats combines participatory design and data science with nordic aesthetics to ensure that it’s both enjoyable and valuable to use their platform. Their platform never sleeps and constantly triages every cardiac device patient using their patent-pending technique. | $2.3M | Seed | Jul 01, 2020 |  |
| Brevel | Brevel developed a disruptive cultivation technology for sustainable, low cost and high quality production of microalgae for various yet untapped markets. The technology is based on high-tech indoor, sterile and fully automated systems which are illuminated from within at high intensity. The technology enables the surprising results of more than90% cost reduction and up to 200 higher yields compared to current alternatives. Brevel is using the advantageous production capabilities to enter multiple markets where microalgae derived products are needed. | $1.3M | Grant | Apr 01, 2020 |  |
| QDevil | QDevil aim of enhancing the science in quantum electronics labs, by enabling scientists to focus their effort on the science, instead of constructing auxiliary equipment that already has been developed in other labs.The products of QDevil have been used and thoroughly tested in some of the world’s leading quantum electronics labs. The initialproduct of QDevil is the QFilter, which has been developed and tested at Harvard University and University of Copenhagen for over five years. | $1.1M | Grant | Mar 01, 2020 |  |

7 of 7 investments shown.

## Co-investors
- [EISMEA](https://shizune.co/investors/profile/easme) — VC Fund, 7 deals together
- [European Innovation Council](https://shizune.co/investors/profile/european-innovation-council) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

## FAQ

### What does EISMEA invest in?

EISMEA invests primarily in Health Care, Biotechnology and Medical startups, most often at Grant and Seed stage. Most of the 7 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact EISMEA?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at EISMEA?

The team at EISMEA includes Cristian Dascalu (EIC Ambassador for Eastern Europe) and Monique Calisti (Expert evaluator and reviewer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co